{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:37:05Z","timestamp":1791329825222,"version":"4.3.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,2,15]]},"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) has a variable clinical course. CD38 expression and IgVH gene mutational status are independent predictors of prognosis, but their relationships and the CD38 cutoff level are unknown. Using cytofluorography, we analyzed CD38 in 148 patients, in 108 of whom we were able to evaluate IgVH mutations, make correlations with disease history, and assess cumulative survival. Three different patient groups were identified by the CD38 expression pattern: a group homogeneously CD38\u2212, a group homogeneously CD38+, and a group characterized by a bimodal profile, because of the concomitant presence of variable proportions of 2 distinct populations, one CD38+ and one CD38\u2212. In CD38 bimodal expression patients the CD38+ subset was significantly more represented in the bone marrow than in the peripheral blood. For IgVH mutations, 11.4% of CD38\u2212, 84.6% of CD38+, and 68.0% of CD38 bimodal expression patients had no mutation. CD38 expression, IgVH mutational status, and traditional prognostic factors were concordant. The progression rate was 12.9% for CD38\u2212, 75.0% for CD38+, and 63.3% for CD38 bimodal expression patients. Only 25.8% of the CD38\u2212patients but 63.3% of the bimodal and 75.0% of CD38+patients were treated. The presence of a CD38+ population, albeit small, correlated with the development of autoimmune manifestations. The CD38\u2212 group has not yet reached the median survival, which is 183 months in the CD38+ group and 156 months in the CD38 bimodal expression group, regardless of the size of the CD38+ population. The presence of a distinct CD38+ population within the leukemic clone, rather than a numerical cutoff definition, correlates with IgVH gene mutational status and, irrespective of its size, identifies CLL patients who will have progressive disease.<\/jats:p>","DOI":"10.1182\/blood-2002-06-1801","type":"journal-article","created":{"date-parts":[[2003,1,30]],"date-time":"2003-01-30T21:36:12Z","timestamp":1043962572000},"page":"1262-1269","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":192,"title":["The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression"],"prefix":"10.1182","volume":"101","author":[{"given":"Paolo","family":"Ghia","sequence":"first","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guida","sequence":"additional","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Stella","sequence":"additional","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gottardi","sequence":"additional","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Geuna","sequence":"additional","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Strola","sequence":"additional","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scielzo","sequence":"additional","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caligaris-Cappio","sequence":"additional","affiliation":[{"name":"From the Department of Oncological Sciences, University of Torino, Torino, Italy; IRCC, Institute for Cancer Research and Treatment, Candiolo (TO) and University Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111821142750700_B1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia.","volume":"333","author":"Rozman","year":"1995","journal-title":"N Engl J Med."},{"key":"2019111821142750700_B2","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood."},{"key":"2019111821142750700_B3","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia.","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med."},{"key":"2019111821142750700_B4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.","volume":"94","author":"Damle","year":"1999","journal-title":"Blood."},{"key":"2019111821142750700_B5","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood."},{"key":"2019111821142750700_B6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V96.1.377.013k56f_377_379","article-title":"Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia.","volume":"96","author":"Maloum","year":"2000","journal-title":"Blood."},{"key":"2019111821142750700_B7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.","volume":"100","author":"Krober","year":"2002","journal-title":"Blood."},{"key":"2019111821142750700_B8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.","volume":"100","author":"Oscier","year":"2002","journal-title":"Blood."},{"key":"2019111821142750700_B9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","article-title":"Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.","volume":"100","author":"Lin","year":"2002","journal-title":"Blood."},{"key":"2019111821142750700_B10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood."},{"key":"2019111821142750700_B11","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","article-title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia.","volume":"98","author":"Del Poeta","year":"2001","journal-title":"Blood."},{"key":"2019111821142750700_B12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood."},{"key":"2019111821142750700_B13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2402339","article-title":"CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.","volume":"16","author":"Durig","year":"2002","journal-title":"Leukemia."},{"key":"2019111821142750700_B14","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.V95.7.2455","article-title":"Immunoglobulin V genes and CD38 expression in CLL.","volume":"95","author":"Hamblin","year":"2000","journal-title":"Blood."},{"key":"2019111821142750700_B15","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood."},{"key":"2019111821142750700_B16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0889-8588(18)30497-0","article-title":"Prognostic factors and clinical staging in chronic lymphocytic leukemia.","volume":"4","author":"Rai","year":"1990","journal-title":"Hematol Oncol Clin North Am."},{"key":"2019111821142750700_B17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest."},{"key":"2019111821142750700_B18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(95)80166-9","article-title":"The human immunoglobulin VH repertoire.","volume":"16","author":"Cook","year":"1995","journal-title":"Immunol Today."},{"key":"2019111821142750700_B19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0167-5699(97)01163-8","article-title":"Unique database numbering system for immunogenetic analysis.","volume":"18","author":"Lefranc","year":"1997","journal-title":"Immunol Today."},{"key":"2019111821142750700_B20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0167-5699(94)90009-4","article-title":"The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire.","volume":"15","author":"Schroeder","year":"1994","journal-title":"Immunol Today."},{"key":"2019111821142750700_B21","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood.V97.9.2777","article-title":"Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.","volume":"97","author":"Granziero","year":"2001","journal-title":"Blood."},{"key":"2019111821142750700_B22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia: prognostic significance.","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer."},{"key":"2019111821142750700_B23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219","article-title":"Clinical staging of chronic lymphocytic leukemia.","volume":"46","author":"Rai","year":"1975","journal-title":"Blood."},{"key":"2019111821142750700_B24","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/blood.V95.4.1199.004k21_1199_1206","article-title":"Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD.","volume":"95","author":"Zupo","year":"2000","journal-title":"Blood."},{"key":"2019111821142750700_B25","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.V88.4.1365.bloodjournal8841365","article-title":"CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis.","volume":"88","author":"Zupo","year":"1996","journal-title":"Blood."},{"key":"2019111821142750700_B26","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM199911113412007","article-title":"Cellular origin of human B-cell lymphomas.","volume":"341","author":"Kuppers","year":"1999","journal-title":"N Engl J Med."},{"key":"2019111821142750700_B27","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood.V97.6.1892","article-title":"CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia.","volume":"97","author":"Thunberg","year":"2001","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/4\/1262\/1262433\/h80403001262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/4\/1262\/1262433\/h80403001262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:14:36Z","timestamp":1574129676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/4\/1262\/105931\/The-pattern-of-CD38-expression-defines-a-distinct"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,15]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-06-1801","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2,15]]}}}